What is PT-141?
An introduction to PT-141 (bremelanotide/Vyleesi), the FDA-approved treatment for HSDD. Learn how it works, who it's for, and what to expect from this medication.
What is PT-141?
PT-141 (bremelanotide, brand name Vyleesi) is an FDA-approved medication for treating low sexual desire (HSDD) in premenopausal women.
Key Facts
| Fact | Detail |
|---|---|
| FDA Approved | Yes (2019) |
| Brand Name | Vyleesi |
| Indication | HSDD in premenopausal women |
| Administration | Self-injection, as needed |
How Does It Work?
PT-141 activates melanocortin-4 receptors in the brain, affecting neural pathways involved in sexual response. Unlike other treatments, it works on desire rather than physical arousal.
Who Is It For?
Vyleesi is approved for premenopausal women with:
- Low sexual desire that causes distress
- Hypoactive Sexual Desire Disorder (HSDD)
It is not approved for:
- Men
- Postmenopausal women
- General sexual enhancement
Common Side Effects
- Nausea (40% of users)
- Flushing
- Headache
- Injection site reactions
Important Notes
- Used on-demand (not daily)
- Maximum 8 uses per month recommended
- Works through the brain, not blood flow
- Requires prescription
This guide is for educational purposes only. PT-141 (Vyleesi) requires a prescription.
Sources & Citations
- 2journalBremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder
pmid-31893927
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.